SoluLinK, Inc. Announces IRS Federal Grant Award to Advance its New Multiplexing and Detection Technology for Research and Diagnostics Applications Used for Accelerating Therapeutics Development
The Qualifying Therapeutic Discovery Project is targeted at therapeutic discovery projects that show a reasonable potential to:
- Result in new therapies to treat areas of unmet medical need or prevent, detect, or treat chronic or acute diseases and conditions,
- Reduce the long-term growth of health care costs in the United States, or
- Significantly advance the goal of curing cancer within 30 years.
About Solulink
Solulink’s proprietary conjugation reagents and easy-to-use linking kits provide unique features and benefits used to link proteins, oligonucleotides, peptides, and antibodies to each other or to a wide range of surfaces including beads, chips, and slides. Solulink markets its products both directly and through distributors and licensing partners worldwide. Solulink is a privately held company located in San Diego, California. For more information, please visit www.solulink.com.
Contact
Steve DeGraw
Solulink, Incorporated
9853 Pacific Heights Blvd. Suite H
San Diego, California 92121
T 858.625.0670
F 858.625.0770
sdegrawsolulink.com